221 related articles for article (PubMed ID: 22262543)
1. Cytotoxic salan-titanium(IV) complexes: high activity toward a range of sensitive and drug-resistant cell lines, and mechanistic insights.
Manna CM; Braitbard O; Weiss E; Hochman J; Tshuva EY
ChemMedChem; 2012 Apr; 7(4):703-8. PubMed ID: 22262543
[TBL] [Abstract][Full Text] [Related]
2. Different ortho and para electronic effects on hydrolysis and cytotoxicity of diamino bis(phenolato) "salan" Ti(IV) complexes.
Peri D; Meker S; Manna CM; Tshuva EY
Inorg Chem; 2011 Feb; 50(3):1030-8. PubMed ID: 21214265
[TBL] [Abstract][Full Text] [Related]
3. High antitumor activity of highly resistant salan-titanium(IV) complexes in nanoparticles: an identified active species.
Meker S; Margulis-Goshen K; Weiss E; Magdassi S; Tshuva EY
Angew Chem Int Ed Engl; 2012 Oct; 51(42):10515-7. PubMed ID: 22961758
[TBL] [Abstract][Full Text] [Related]
4. Major impact of N-methylation on cytotoxicity and hydrolysis of salan Ti(IV) complexes: sterics and electronics are intertwined.
Meker S; Manna CM; Peri D; Tshuva EY
Dalton Trans; 2011 Oct; 40(38):9802-9. PubMed ID: 21874187
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic titanium salan complexes: surprising interaction of salan and alkoxy ligands.
Immel TA; Groth U; Huhn T
Chemistry; 2010 Mar; 16(9):2775-89. PubMed ID: 20104550
[TBL] [Abstract][Full Text] [Related]
6. Differential cytotoxicity induced by the Titanium(IV)Salan complex Tc52 in G2-phase independent of DNA damage.
Pesch T; Schuhwerk H; Wyrsch P; Immel T; Dirks W; Bürkle A; Huhn T; Beneke S
BMC Cancer; 2016 Jul; 16():469. PubMed ID: 27412346
[TBL] [Abstract][Full Text] [Related]
7. Trans titanium(IV) complexes of salen ligands exhibit high antitumor activity.
Tzubery A; Tshuva EY
Inorg Chem; 2011 Sep; 50(17):7946-8. PubMed ID: 21797239
[TBL] [Abstract][Full Text] [Related]
8. New insights on the active species and mechanism of cytotoxicity of salan-Ti(IV) complexes: a stereochemical study.
Manna CM; Armony G; Tshuva EY
Inorg Chem; 2011 Oct; 50(20):10284-91. PubMed ID: 21923127
[TBL] [Abstract][Full Text] [Related]
9. Unexpected influence of stereochemistry on the cytotoxicity of highly efficient Ti(IV) salan complexes: new mechanistic insights.
Manna CM; Armony G; Tshuva EY
Chemistry; 2011 Dec; 17(50):14094-103. PubMed ID: 22076809
[TBL] [Abstract][Full Text] [Related]
10. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
11. Insights into molecular mechanism of action of salan titanium(IV) complex with in vitro and in vivo anticancer activity.
Miller M; Braitbard O; Hochman J; Tshuva EY
J Inorg Biochem; 2016 Oct; 163():250-257. PubMed ID: 27090292
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity and hydrolysis of trans-Ti(IV) complexes of salen ligands: structure-activity relationship studies.
Tzubery A; Tshuva EY
Inorg Chem; 2012 Feb; 51(3):1796-804. PubMed ID: 22220885
[TBL] [Abstract][Full Text] [Related]
13. Anti-proliferative activity of nano-formulated phenolato titanium(IV) complexes against cancer cells.
Meker S; Margulis-Goshen K; Weiss E; Braitbard O; Hochman J; Magdassi S; Tshuva EY
ChemMedChem; 2014 Jun; 9(6):1294-8. PubMed ID: 24677761
[TBL] [Abstract][Full Text] [Related]
14. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
15. Highly Stable Tetra-Phenolato Titanium(IV) Agent Formulated into Nanoparticles Demonstrates Anti-Tumoral Activity and Selectivity.
Meker S; Braitbard O; Margulis-Goshen K; Magdassi S; Hochman J; Tshuva EY
Molecules; 2015 Oct; 20(10):18526-38. PubMed ID: 26473816
[TBL] [Abstract][Full Text] [Related]
16. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
17. [RuII(η⁵-C₅H₅)(bipy)(PPh₃)]⁺, a promising large spectrum antitumor agent: cytotoxic activity and interaction with human serum albumin.
Tomaz AI; Jakusch T; Morais TS; Marques F; de Almeida RF; Mendes F; Enyedy EA; Santos I; Pessoa JC; Kiss T; Garcia MH
J Inorg Biochem; 2012 Dec; 117():261-9. PubMed ID: 22877927
[TBL] [Abstract][Full Text] [Related]
18. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression.
Jain D; Patel N; Shelton M; Basu A; Roque R; Siede W
Cancer Chemother Pharmacol; 2010 Oct; 66(5):945-52. PubMed ID: 20101404
[TBL] [Abstract][Full Text] [Related]
20. Study of the cytotoxicity and particle action in human cancer cells of titanocene-functionalized materials with potential application against tumors.
García-Peñas A; Gómez-Ruiz S; Pérez-Quintanilla D; Paschke R; Sierra I; Prashar S; del Hierro I; Kaluđerović GN
J Inorg Biochem; 2012 Jan; 106(1):100-10. PubMed ID: 22112846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
